Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
FIVE PRIME THERAPEUTICS, INC. (FPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/16/2021 8-K Resignation/termination of a director
Docs: "Tenth Amended and Restated Certificate of Incorporation of Five Prime Therapeutics, Inc.",
"Amended and Restated Bylaws of Five Prime Therapeutics, Inc.",
"Form of Gross-Up Agreement"
04/15/2021 8-K Other Events  Interactive Data
03/04/2021 8-K Quarterly results
01/15/2021 8-K Quarterly results
01/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide presentation",
"Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers",
"Slide presentation"
11/17/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Five Prime Announces Closing of Upsized Public Offering of Common Stock"
11/13/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company, Cowen and Company, LLC and SVB Leerink LLC",
"Opinion of Cooley LLP",
"Five Prime Announces Pricing of Upsized Public Offering of Common Stock"
11/10/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide presentation",
"Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer",
"Slide presentation"
11/03/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Five Prime Therapeutics Reports Third Quarter 2020 Results"
11/02/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Five Prime to Present First Pre-clinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting • Data will be presented during late-breaker abstract virtual poster sessions on November 11 and November 13, 2020 SOUTH SAN FRANCISCO, Calif.——November 02, 2020— Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced the upcoming virtual poster presentation of the first preclinical data from its anti-CCR8 antibody, FPA157 program, at the Society for Immunotherapy of Cancer 35 th Anniversary Annual Meeting being held from November 9-14, 2020. Late-breaker Virtual Poster Presentation and Q&A Details: Title: Development of FPA157, an anti..."
09/03/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
09/01/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/06/2020 8-K Quarterly results
05/20/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/07/2020 8-K Quarterly results
04/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
04/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer"
02/27/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
02/18/2020 8-K Quarterly results
01/21/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/13/2020 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
12/26/2019 8-K Quarterly results
11/25/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/06/2019 8-K Quarterly results
Docs: "Five Prime Therapeutics Reports Third Quarter 2019 Results SOUTH SAN FRANCISCO, Calif.——November 6, 2019— Five Prime Therapeutics , Inc. , a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third quarter and provided an update on the company's recent activities. “We have advanced all of our wholly-owned programs according to our plan for 2019,” said Willilam Ringo, Chairman and interim Chief Executive Officer of Five Prime Therapeutics. “As we approach 2020, we have repositioned Five Prime with a focus on prioritizing our pipeline based on upcoming data readouts, while also extending our cash runway, in order to maximize the long-term potential of the company.” Third Quarter 201..."
10/10/2019 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities  Interactive ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/09/2019 8-K Quarterly results
09/19/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/07/2019 8-K Quarterly results
07/31/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 29, 2019 Five Prime Therapeutics, Inc. Delaware 001-36070 26-0038620 111 Oyster Point Boulevard South San Francisco, California 94080 Registrant's telephone number, including area code: 365-5600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#97..."
06/28/2019 8-K Quarterly results
06/24/2019 8-K Quarterly results
06/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 7, 2019 Five Prime Therapeutics, Inc. Delaware 001-36070 26-0038620 111 Oyster Point Boulevard South San Francisco, California 94080 Registrant's telephone number, including area code: 365-5600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#974..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy